1. Home
  2. UA vs ACAD Comparison

UA vs ACAD Comparison

Compare UA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UA
  • ACAD
  • Stock Information
  • Founded
  • UA 1996
  • ACAD 1993
  • Country
  • UA United States
  • ACAD United States
  • Employees
  • UA N/A
  • ACAD N/A
  • Industry
  • UA Apparel
  • ACAD Biotechnology: Pharmaceutical Preparations
  • Sector
  • UA Consumer Discretionary
  • ACAD Health Care
  • Exchange
  • UA Nasdaq
  • ACAD Nasdaq
  • Market Cap
  • UA 2.6B
  • ACAD 2.5B
  • IPO Year
  • UA N/A
  • ACAD 2004
  • Fundamental
  • Price
  • UA $6.15
  • ACAD $21.98
  • Analyst Decision
  • UA Strong Buy
  • ACAD Buy
  • Analyst Count
  • UA 1
  • ACAD 14
  • Target Price
  • UA $9.00
  • ACAD $27.08
  • AVG Volume (30 Days)
  • UA 3.8M
  • ACAD 3.0M
  • Earning Date
  • UA 05-13-2025
  • ACAD 05-07-2025
  • Dividend Yield
  • UA N/A
  • ACAD N/A
  • EPS Growth
  • UA N/A
  • ACAD N/A
  • EPS
  • UA N/A
  • ACAD 1.37
  • Revenue
  • UA $5,164,310,000.00
  • ACAD $996,283,000.00
  • Revenue This Year
  • UA N/A
  • ACAD $13.49
  • Revenue Next Year
  • UA $3.03
  • ACAD $10.58
  • P/E Ratio
  • UA N/A
  • ACAD $15.68
  • Revenue Growth
  • UA N/A
  • ACAD 22.42
  • 52 Week Low
  • UA $4.62
  • ACAD $13.40
  • 52 Week High
  • UA $10.62
  • ACAD $25.23
  • Technical
  • Relative Strength Index (RSI)
  • UA 53.16
  • ACAD 70.12
  • Support Level
  • UA $5.95
  • ACAD $21.09
  • Resistance Level
  • UA $6.41
  • ACAD $22.62
  • Average True Range (ATR)
  • UA 0.24
  • ACAD 1.18
  • MACD
  • UA -0.01
  • ACAD 0.06
  • Stochastic Oscillator
  • UA 47.65
  • ACAD 60.65

About UA Under Armour Inc. Class C

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: